Application Of Interferon-Gamma Release Assay In Extrapulmonary Tuberculosis Diagnosis, T-Lymphocyte Regulation, And Efficacy Evaluation In Northwest China

Although the interferon-gamma release assay (IGRA) has become a widely accepted means for the diagnosis of tuberculosis (TB), there are limited data on IGRA performance in the diagnosis of extrapulmonary TB in Northwest China. Using a retrospective cohort design, we enrolled 156 patients with confirmed extrapulmonary tuberculosis. The sensitivity and specificity of TSOPT. TB as well as the area under the receiver operating characteristic curve were analyzed, to compare changes of TSOPT. TB values during treatment and its correlation with T-lymphocyte subsets. The pooled sensitivity and specificity of the TB-IGRA were 71.3% and 65.9%, respectively, and the optimum area under the curve (AUC) was 0.644. Of these, the AUC of IGRA, PPD, and TB antibody of tuberculous empyema obtained by TSPOT. TB were 0.738, 0.664, and 0.634, respectively. The AUC of IGRA, PPD, and TB antibody of lymphatic tuberculosis were 0.726, 0.747, and 0.647, respectively. The AUC of IGRA, PPD, and TB antibody of spinal, bone, and joint tuberculosis were 0.670, 0.588, and 0.642, respectively, while the AUC of IGRA, PPD, and TB antibody of other tuberculosis were 0.786, 0.690, and 0.644, respectively. All of the results were better than those obtained by conventional experimental methods. After antituberculosis treatment, the positive rate and concentration of TSOPT. TB after drug withdrawal were significantly decreased (P<0.05). TSPOT. TB can still be a good test for the diagnosis of extrapulmonary tuberculosis. Changes in the TSPOT. TB test after antituberculosis treatment can be an auxiliary indicator of the therapeutic effect and drug withdrawal.